Crossmark

52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience

Crossref DOI link: https://doi.org/10.1016/j.ad.2023.08.019

Published Print: 2024-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Melgosa Ramos, F.J.

Mateu Puchades, A.

Matáix-Díaz, J.

Schneller-Pavelescu, L.

Belinchón-Romero, I.

Santos Alarcón, S.
License Information

Text and Data Mining valid from 2024-07-01

Text and Data Mining valid from 2024-07-01

Version of Record valid from 2024-03-27
More Information

This article is maintained by: Elsevier

Article Title: 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2023.08.019

Content Type: simple-article

Copyright: © 2024 AEDV. Published by Elsevier España, S.L.U.